

DIGITAL BIOMARKERS CONFERENCE AGENDA

Use of Biosensors in Clinical Trials: Barriers & Solutions to the Current Landscape

Bethesda North Marriott Conference Center
5701 Marinelli Road, North Bethesda, MD 20852

March 31, 2016

Time	Topic	Presenter	Duration
8:00 a.m.	Breakfast	All	30 minutes
8:30 a.m.	Welcome & Objectives of the Meeting <ul style="list-style-type: none"> Unmet Needs 	Stephen Arnerić, PhD <i>Executive Director, CAMD, C-Path</i>	15 minutes
	Health Measurements		
8:45 a.m.	<i>Digital Biomarkers: Life Kinetics as Outcomes in Clinical Trials</i>	Jeffrey Kaye, MD <i>Director, NIA - Layton Aging & Alzheimer's Disease Center; Director, NIA - ORCATECH - Oregon Center for Aging & Technology; Professor of Neurology and Biomedical Engineering</i>	45 minutes
9:30 a.m.	<i>Repurposing Consumer Technology for Digital Biomarkers</i>	Max Little, PhD <i>Associate Professor, Aston University; TED Fellow; Visiting Associate Professor, MIT</i>	20 minutes
9:50 a.m.	<i>Health Measurements Panel Discussion</i>	All	20 minutes
10:10 a.m.	Break		15 minutes
	Regulatory Considerations		
10:25 a.m.	<i>Why do Standards Matter?</i>	Rebecca D. Kush, PhD <i>President & CEO, CDISC</i>	20 minutes
10:45 a.m.	<i>Informed Consent</i>	John Wilbanks, BA <i>Senior Fellow, FasterCures; Chief Commons Officer, Sage Bionetworks</i>	20 minutes
11:05 a.m.	<i>Information Exchange and Data Transformation (INFORMED) Initiative</i>	Sean Khozin, MD, MPH <i>Senior Medical Officer, FDA; Project Lead of Information Exchange and Data Transformation (INFORMED)</i>	20 minutes
11:25 a.m.	<i>Regulatory Considerations Panel Discussion</i>	All	20 minutes
	Multiple Sclerosis		
11:45 a.m.	<i>Advances Towards Remote Assessment of Disease and Relapse in MS patients</i>	Jane Rhodes, MBA, PhD <i>Senior Director of New Initiatives for the Value Based Medicine team in the Biogen innovation hub</i>	20 minutes
12:05 p.m.	<i>Multiple Sclerosis Discussion</i>	All	10 minutes

DIGITAL BIOMARKERS CONFERENCE AGENDA

Use of Biosensors in Clinical Trials: Barriers & Solutions to the Current Landscape

12:15 p.m.	Lunch	All	60 minutes
	Alzheimer's Disease		
1:15 p.m.	<i>Use of Internet Based Assessment for Tracking the Course of Early Alzheimer's Disease with Potential for Determining Response to Treatment</i>	Paul Maruff, PhD Chief Science Officer, CogState, Ltd.	20 minutes
1:35 p.m.	<i>Cognitive Assessment in the Digital Era</i>	Rhoda Au, MBA, PhD Prof. of Neurology, Director of Neuropsychology for the Framingham Heart Study (FHS) and serves to facilitate the collaboration between FHS and the Boston University Alzheimer's Disease Center	20 minutes
1:55 p.m.	<i>Real-world Digital Biomarkers from Symptomatic Community Population with Cognitive Impairment</i>	John Hall, PhD SVP, Commercial Operations IXICO Ken Tubman, PhD VP, Healthcare Technology IXICO	20 minutes
2:15 p.m.	<i>Alzheimer's Disease Panel Discussion</i>	All	20 minutes
	Parkinson's Disease		
2:35 p.m.	<i>Musings on Measuring Movement</i>	Jesse M. Cedarbaum, MD Vice President, Movement and Neuromuscular Disorders Clinical Development, Biogen	20 minutes
2:55 p.m.	<i>Digital Biomarkers in Neurology</i>	Ray Dorsey, MD, MBA David M. Levy Professor in Neurology, Director, CHET	20 minutes
3:15 p.m.	<i>Parkinson's Disease Panel Discussion</i>	All	20 minutes
3:35 p.m.	Break	All	15 minutes
	Huntington's Diseases		
3:50 p.m.	<i>Digital Biomarkers for Huntington's Disease: Promises and Challenges</i>	Ottavio Vitolo, MD, MMS Senior Director, Head of Neuromuscular Clinical Research, Rare Disease Research Unit, Research Project Lead in Huntington's disease, Pfizer Inc.	20 minutes
4:10 p.m.	<i>Challenges & Promises of digital biomarkers in the quantification of motor function</i>	Spyros Papapetropoulos, MD, PhD Vice President, Global Development Head, Neurodegenerative Diseases at Teva Pharmaceuticals	20 minutes
4:30 p.m.	<i>Huntington's Disease Panel Discussion</i>	All	20 minutes
4:50 p.m.	Conclusion	Stephen Arnerić, PhD Executive Director, CAMD, C-Path	10 minutes